| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2014184778 |
| Title |
Pyrimidin-4-Yl)Oxy)-1H-Indole-1-Carboxamide Derivatives and Use Thereof. |
| Abstract |
This invention relates to certain metabolites of N-(1-methyl-5-(trifluoromethyl)-1H- pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide In particular, the present invention relates to pharmaceutical compositions comprising these metabolites, as well as processes for their preparation and their use in the treatment of diseases. |
| Applicant(s) |
Novartis Ag |
| Representative Drug(s) |
D0G1YI |
Drug Info
|
IC50 < 1 nM |
Click to Show More |
[1] |
|
2
|
D0JU8E
|
Drug Info
|
IC50 < 1 nM
|
[1] |
| Patent ID |
WO2016057726 |
| Title |
Human Anti-Vegfr-2/Kdr Antibodies. |
| Abstract |
The invention relates to antibodies that bind to VEGFR-2. The antibodies are used for treating neoplastic diseases, hyperproliferative disorders, and angiogenic disorders and can be used alone or in combination with other agents. |
| Applicant(s) |
Kadmon Corporation, Llc |
| Representative Drug(s) |
D01AXK |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014197313 |
| Title |
Novel Compounds and Uses Thereof. |
| Abstract |
The present invention provides novel compounds of any one of Formulae (I)-(IV), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of Formulae (I)-(IV) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF)), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof. |
| Applicant(s) |
Kala Pharmaceuticals, Inc |
| Representative Drug(s) |
D06BTN |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2014019520 |
| Title |
Tumor Vessel Specific Binding Polypeptide and Application Thereof. |
| Abstract |
The present invention provides a polypeptide in sequence of FF/YEXWGVK and derivatives thereof. The polypeptide and the derivatives thereof can perform specific binding to VEGFR-2, can be used as cont. |
| Applicant(s) |
Suzhou Institute of Nano-Tech and Nano-Bionics (Sinano), Cas |
| Representative Drug(s) |
D08XAY |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2005030140 |
| Title |
C-Met Modulators and Methods of Use. |
| Abstract |
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. |
| Applicant(s) |
Exelixis, Inc |
| Representative Drug(s) |
D0IQ6P |
Drug Info
|
N.A. |
[2] |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20120219522 |
| Title |
Preparation of Substituted Quinoline Compounds As Protein Tyrosine Kinase Modulators. |
| Applicant(s) |
Sunshine Lake Pharma Co., Ltd |
| Representative Drug(s) |
D08OXH |
Drug Info
|
IC50 = 23 nM |
[1] |
| Patent ID |
US20080255172 |
| Title |
Preparation of Pyrimidine Derivatives for Treating Angiogenesis-Related Disorders. |
| Applicant(s) |
Hutchison Medipharma Enterprises Limited |
| Representative Drug(s) |
D06HEO |
Drug Info
|
N.A. |
[1] |
| Patent ID |
US9029386 |
| Title |
Inhibitors of Kinase Activity. |
| Applicant(s) |
Ym Biosciences Australia Pty |
| Representative Drug(s) |
D0AK1F |
Drug Info
|
N.A. |
[3] |
| Patent ID |
US20130137660 |
| Title |
Inhibitors of Kinase Activity. |
| Applicant(s) |
Ym Biosciences Australia Pty |
| Representative Drug(s) |
D0AK1F |
Drug Info
|
N.A. |
[3] |
